ClinicalTrials.gg
RecruitingNCT07572383Updated Jul 14, 2026

Advanced Imaging to Assess the Effect of Immunosuppression on Progressive Fibrosis

A Phase 2 interventional study of [68Ga]CBP8 and Gadoterate Meglumine in Interstitial Lung Disease and Pulmonary Fibrosis, sponsored by Peter Caravan. Recruiting at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-07-14.

Primary conditionPulmonary FibrosisRegistry: Lung Diseases, InterstitialReclassifiedWhy we changed it
Registry
Lung Diseases, Interstitial — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pulmonary Fibrosis
Why
  1. The study's listed conditions name Pulmonary Fibrosis, a narrower term within Lung Diseases, Interstitial.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Peter Caravan · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Pulmonary Fibrosis with a site in United States — 30 open to participants now, 42 under way, 5 of them phase 3. Pulmonary Fibrosis · United States.

Planned enrollment
76th of 90
15 · median 50
Started
2026
with 3 others
Phase 2
43 of 128
9 open now
Primary completion
2028-12
later than 31 of 38 live
Registered
127th of 128
by date

Among the 128 studies in Pulmonary Fibrosis with a site in United States, this one is the 76th largest by planned enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2026, is one of 43 in phase 2, reaches primary completion later than 31 of the 38 other live ones, and was the 127th registered.

Pulmonary Fibrosis

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

Browse Pulmonary Fibrosis studies →

Open to participants now

30 of the 128 studies in Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 30 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate how immunosuppression treatment affects measurements of active collagen deposition using [68Ga]CBP8 positron emission tomography (PET) and tissue injury using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) in individuals with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD).

Read the detailed description

15 different subjects with non-IPF ILD starting immunosuppression treatment for their underlying ILD will be enrolled. Participants will undergo [68Ga]CBP8 PET and DCE-MRI prior to and 12 weeks after treatment initiation to determine the effects of immunosuppressive treatment on PET measurements of collagen deposition and selected DCE-MRI-derived measurements.

03

Conditions studied

  • Interstitial Lung Disease
  • Pulmonary Fibrosis

Browse trials for

04

In context

Pulmonary Fibrosis Reclassified

342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.

This study's planned enrollment of 15 is below the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.

Browse Pulmonary Fibrosis studies →

Lead sponsor

Peter Caravan is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Compared within Pulmonary Fibrosis, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Lung Diseases, Interstitial. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18-80 with a diagnosis of chronic pneumonitis, connective tissue-associated ILD (due to rheumatoid arthritis, systemic sclerosis, mixed connective tissue disease), or undifferentiated ILD.
  2. Starting treatment with mycophenolate mofetil, mycophenolate sodium, and / or prednisone for clinically indicated non-IPF ILD treatment.
  3. Pulmonary fibrosis, defined as honeycombing, traction bronchiectasis, or reticular opacities on high-resolution computed tomography (HRCT) performed within 1 year to or at Visit 1.
  4. Forced vital capacity (FVC) of >/= 45% and diffusing capacity of the lungs for carbon monoxide (DLCO) >/= 25% predicted on PFTs performed at Visit 1.

Exclusion criteria

Exclusion criteria:

  1. Current or prior exposure to FDA approved anti-fibrotic therapy.
  2. Extent of emphysema greater than extent of fibrosis.
  3. Pregnancy or plans to become pregnant at baseline or during follow-up.
  4. to MRI.
  5. Contraindications to receiving gadolinium-based contrast agents.
  6. Research-related radiation exposure exceeds 50 millisievert (mSv) in the prior year.
  7. Estimated (eGFR) \< 30 mL/min (only for individuals with a history of chronic kidney disease).
  8. pulmonary hypertension (PH) defined by use of pulmonary vasodilatory therapy.
  9. Respiratory infection within the prior 6 weeks.
  10. Smoking of any kind within the prior 6 months.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Participants with Pulmonary Fibrosis

    Participants with non-idiopathic pulmonary fibrosis interstitial lung disease (non-IPF ILD) will receive \[68Ga\]CBP8 and undergo PET combined with dynamic contrast-enhanced MRI prior to and 12 weeks after starting clinically-prescribed immunosuppression for treatment of non-IPF ILD

    Drug: [68Ga]CBP8 · Drug: Gadoterate Meglumine

Interventions

  • DrugCBP-8 gallium GA-68Studies of CBP-8 gallium GA-68CBP-8 gallium GA-68 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Participants will receive a single intravenous injection of up to 350 MBq of \[68Ga\]CBP8

  • DrugGadoterate Meglumine

    Participants will receive a single intravenous injection of 0.05 mmol/kg gadoterate meglumine during DCE-MRI

07

What researchers measure

Primary outcomes

  1. Change in SUVmax25 over the entire lungs

    Changes in lung collagen uptake will be measured using the PET probe \[68\]Ga-CBP8. Measurements will be made using the mean of the upper quartile of standardized uptake values (SUVmax25). Primary \[68Ga\]CBP8-PET outcome.

    Time frame: From baseline to 12 weeks

  2. Change in the rate of contrast washin (kwashin) over the entire lungs

    Changes in rate of contrast washin will be measured using dynamic-contrast enhanced MRI. Primary DCE-MRI outcomes.

    Time frame: From baseline to 12 weeks

Secondary outcomes

  1. Change in SUVmean over the entire lungs

    Changes in lung collagen uptake will be measured using the PET probe \[68\]Ga-CBP8. Measurements will be made using the mean standardized uptake value (SUVmean).

    Time frame: From baseline to 12 weeks

  2. Change in SUVmax over the entire lungs

    Changes in lung collagen uptake will be measured using the PET probe \[68\]Ga-CBP8. Measurements will be made using the max standardized uptake value (SUVmax).

    Time frame: From baseline to 12 weeks

  3. Change in peak enhancement over the entire lungs

    Changes in peak enhancement will be measured using dynamic-contrast enhanced MRI

    Time frame: From baseline to 12 weeks

  4. Change in time to peak over the entire lungs

    Changes in time to peak will be measured using dynamic-contrast enhanced MRI

    Time frame: From baseline to 12 weeks

  5. Change in the area under the curve at 60 seconds (AUC60) over the entire lungs

    Changes in the area under the curve at 60 seconds will be measured using dynamic-contrast enhanced MRI

    Time frame: From baseline to 12 weeks

  6. Change in the rate of contrast washout (kwashout) over the entire lungs

    Changes in the rate of contrast washout will be measured using dynamic-contrast enhanced MRI.

    Time frame: From baseline to 12 weeks

08

Study locations

1 of 1 sites recruiting
09

References and documents

Publications

  • Izquierdo-Garcia D, Desogere P, Fur ML, Shuvaev S, Zhou IY, Ramsay I, Lanuti M, Catalano OA, Catana C, Caravan P, Montesi SB. Biodistribution, Dosimetry, and Pharmacokinetics of 68Ga-CBP8: A Type I Collagen-Targeted PET Probe. J Nucl Med. 2023 May;64(5):775-781. doi: 10.2967/jnumed.122.264530. Epub 2022 Dec 8. PubMed 37116909 ↗
  • Montesi SB, Izquierdo-Garcia D, Desogere P, Abston E, Liang LL, Digumarthy S, Seethamraju R, Lanuti M, Caravan P, Catana C. Type I Collagen-targeted Positron Emission Tomography Imaging in Idiopathic Pulmonary Fibrosis: First-in-Human Studies. Am J Respir Crit Care Med. 2019 Jul 15;200(2):258-261. doi: 10.1164/rccm.201903-0503LE. No abstract available. PubMed 31161770 ↗
  • Desogere P, Tapias LF, Hariri LP, Rotile NJ, Rietz TA, Probst CK, Blasi F, Day H, Mino-Kenudson M, Weinreb P, Violette SM, Fuchs BC, Tager AM, Lanuti M, Caravan P. Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models. Sci Transl Med. 2017 Apr 5;9(384):eaaf4696. doi: 10.1126/scitranslmed.aaf4696. PubMed 28381537 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Dec 2028, 31 months after the start.

Of 33 phase 2 interventional studies under Pulmonary Fibrosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 58. This study's planned 31 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
May 7, 2026
StartActual
May 14, 2026
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2028
Last update
Jul 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07572383
Lead sponsor
Peter Caravan
Responsible party
Peter Caravan (Sponsor, Massachusetts General Hospital) — Sponsor-investigator
First posted
May 7, 2026
Start date
May 14, 2026
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2028 (estimated)
Last update
Jul 14, 2026

Study contacts

Sydney Montesi, MD
Contact
sbmontesi@mgb.org
617 724 4030
Caroline Fromson
Contact
cfromson@mgh.harvard.edu
617 643 3260
Sydney Montesi, MD
principal investigator · Massachusetts General Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CBP-8 gallium GA-68

Start the discussion